BPC-157 vs TB-500
Written and maintained by the AVERON Research Desk · Last reviewed September 2026
BPC-157 and TB-500 are the two most widely discussed repair peptides, and they are so often used together that many people assume they are variations of the same thing. They are not. They are unrelated molecules with different origins and different proposed mechanisms. What they share is a large reputation built almost entirely on animal research.
Where they come from
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. Most of its research comes from one group at the University of Zagreb.
TB-500 is a synthetic fragment of thymosin beta-4, a natural 43-amino-acid protein found in almost every cell, which regulates actin, the structural filament cells use to move. The name is used inconsistently: some products sold as TB-500 are the fragment, others the full protein.
How they are proposed to work
BPC-157 is usually described as acting locally, near where it is applied, through blood vessel growth, the nitric oxide system and repair signalling.
TB-500 is usually described as acting throughout the body, by supporting cell migration to damaged tissue.
That difference — local versus systemic — is the main reason people combine them. None of these mechanisms has been confirmed in people.
Side by side
| BPC-157 | TB-500 | |
|---|---|---|
| Length | 15 amino acids | Short fragment of a 43-amino-acid protein |
| Origin | Gastric juice protein | Thymosin beta-4 |
| Proposed action | Local | Systemic |
| Human trials | None completed | None for the fragment |
| Evidence level | Preclinical only | Preclinical only |
| Anti-doping | WADA S0, named explicitly | WADA S2, named explicitly |
| AVERON name | BP-157 | TB-5 |
The evidence for each
For BPC-157, a 2025 systematic review in the HSS Journal found 36 studies in orthopaedic and sports medicine: 35 preclinical and one small clinical report without a control group.
For TB-500, most research concerns the full thymosin beta-4 protein rather than the fragment. The limited human studies of the full protein tested eye drops and wound gels, not injections of TB-500.
Using them together
Combining two compounds does not combine their evidence. No trial has tested BPC-157 and TB-500 together. The combination, sold as the Wolverine blend, is supported only by the separate animal research on each. See peptide blends.
Shared concerns
Both are associated with the growth of new blood vessels, which has led some researchers to raise a theoretical concern about effects on existing tumours. This has not been studied in people. Long-term safety is unknown for both.
In sport
Both are explicitly named on WADA's Prohibited List and both are prohibited at all times. Many athletes believe BPC-157 in particular is allowed. It is not.
Frequently asked questions
Doses mentioned on this page are the arms of published trials, given to describe their results. They are not guidance.
Sources
- Vasireddi N, Hahamyan H, Salata MJ, et al.. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, 2025;21(4):485–495. Link
- Scoping review. Thymosin beta-4 and TB-500 in tissue healing, regeneration, and musculoskeletal repair. Applied Sciences, 2026;16(12):6202. Link
- World Anti-Doping Agency. The Prohibited List. WADA. Link